Lobeglitazone vs Pioglitazone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: PPAR-gamma · full Type 2 Diabetes pipeline

Lobeglitazone · Duvie

Marketed by Chong Kun Dang Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT02002611 · Phase 1 · completed

Every participant received both lobeglitazone and warfarin, so there is no separate group showing what would have happened without lobeglitazone, and nobody was blinded to treatment. The measures collected were drug-level readings for a drug-interaction check, not a symptom or disease-based result, so this trial offers only limited evidence about lobeglitazone's own effects.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change from baseline in Glycosylated Hemoglobin (HbA1c) (Baseline, 24 weeks): HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. (met)

Result source: NCT03739125

Pioglitazone · Actos

Marketed by Takeda Pharmaceutical Company

Approved in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06989723 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLobeglitazonePioglitazone
HbA1c, change—Not posted · NCT01106131-1.0% vs -0.3%−0.8 vs placebo300 mg · wk 26 · n 112NCT01106690
102 other results
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.8% vs -0.2% 10 mg · wk 24 · n 149 · Phase 3 · primary NCT01095666
  • -0.8% vs -0.2% 5 mg · wk 24 · n 146 · Phase 3 · primary NCT01095666
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.3% vs -0.4% wk 16 · n 63 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -0.4% vs 0.4% wk 12 · n 66 · Phase 3 · primary NCT00372060
  • -1.2% vs -0.9% 45 mg · wk 54 · n 171 · Phase 3 · primary NCT00722371
  • -0.9% vs -0.4% 45 mg · wk 30 · n 134 · Phase 3 · primary NCT01183013
  • -1.2% vs -1.1% 45 mg · wk 24 · n 171 · Phase 3 · primary NCT00722371
  • -1.4% vs -0.9% 100 mg/15 mg · wk 54 · n 179 · Phase 3 · primary NCT00722371
  • -1.5% vs -0.9% 100 mg/30 mg · wk 54 · n 173 · Phase 3 · primary NCT00722371
  • -1.8% vs -0.9% 100 mg/45 mg · wk 54 · n 188 · Phase 3 · primary NCT00722371
  • -2.4% vs -1.9% 100 mg q.d. + 45 mg q.d. · wk 54 · n 161 · Phase 3 · primary NCT01028391
  • -1.5% vs -1.1% 100 mg/15 mg · wk 24 · n 179 · Phase 3 · primary NCT00722371
  • -1.6% vs -1.1% 100 mg/30 mg · wk 24 · n 173 · Phase 3 · primary NCT00722371
  • -1.8% vs -1.1% 100 mg/45 mg · wk 24 · n 188 · Phase 3 · primary NCT00722371
  • -2.4% vs -1.5% 100 mg q.d. + 30 mg q.d. · wk 24 · n 251 · Phase 3 · primary NCT00397631
  • -1.2% vs -0.9% 30 mg · wk 54 · n 181 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.4% 30 mg · wk 30 · n 134 · Phase 3 · primary NCT01183013
  • -1.2% vs -1.1% 30 mg · wk 24 · n 181 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.7% vs -0.9% 15 mg · wk 54 · n 163 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.4% 15 mg · wk 30 · n 124 · Phase 3 · primary NCT01183013
  • -0.9% vs -1.1% 15 mg · wk 24 · n 163 · Phase 3 · primary NCT00722371
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.4% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.6% vs -0.9% wk 52 · n 50 · Phase 3 · secondary NCT00372060
  • -0.3% vs -0.4% wk 12 · n 63 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.3% vs -0.4% wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1% vs -0.2% wk 4 · n 63 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 45 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 45 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 45 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 45 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 30 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 30 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 30 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.4% 30 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 30 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.8% vs -0.4% 15 mg · wk 30 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 15 mg · wk 24 · n 124 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 15 mg · wk 18 · n 124 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.4% 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 15 mg · wk 6 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.9% vs -0.4% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.4% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.4% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.4% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs 0.2% wk 12 · n 12 · Phase 2 · secondary NCT00443755
Body weight, change (kg)—Not posted · NCT011061311.1 vs 1.0+0.1 vs placebo25 mg QD · wk 26 · n 189NCT00286494
21 other results
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -2.6 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT01095666
  • -1.8 vs -0.7 5 mg · wk 24 · n 147 · Phase 3 · secondary NCT01095666
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.6 wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
HbA1c below 7%—Not posted · NCT0110613133% vs 17.5%+15.5 vs placebo10 mg · wk 24 · n 149NCT01095666
4 other results
  • 32.9% vs 17.5% 5 mg · wk 24 · n 146 · Phase 3 · secondary NCT01095666
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 31.7% vs 30% wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
Fasting plasma glucose, change—Not posted · NCT01106131-1.8 vs 0.1−2 vs placebo300 mg · wk 26 · n 112NCT01106690
105 other results
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -1.5 vs 0.0 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT01095666
  • -1.2 vs 0.0 5 mg · wk 24 · n 146 · Phase 3 · secondary NCT01095666
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.1 vs -0.3 wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.2 vs -0.4 wk 12 · n 63 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.2 wk 12 · n 66 · Phase 3 · secondary NCT00372060
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.0 vs -0.3 wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • 0.3 vs -0.3 wk 4 · n 63 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1.9 vs -0.7 45 mg · wk 54 · n 181 · Phase 3 · secondary NCT00722371
  • -1.6 vs -0.1 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.8 vs 0 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.3 45 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -2.1 vs -1.4 45 mg · wk 24 · n 181 · Phase 3 · secondary NCT00722371
  • -1.6 vs -0.4 45 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -1.4 vs -0.4 45 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.2 45 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -1.9 vs -0.7 100 mg/15 mg · wk 54 · n 189 · Phase 3 · secondary NCT00722371
  • -2.1 vs -0.7 100 mg/30 mg · wk 54 · n 181 · Phase 3 · secondary NCT00722371
  • -2.6 vs -0.7 100 mg/45 mg · wk 54 · n 193 · Phase 3 · secondary NCT00722371
  • -3.4 vs -2.9 100 mg q.d. + 45 mg q.d. · wk 54 · n 163 · Phase 3 · secondary NCT01028391
  • -2.3 vs -1.4 100 mg/15 mg · wk 24 · n 189 · Phase 3 · secondary NCT00722371
  • -2.6 vs -1.4 100 mg/30 mg · wk 24 · n 181 · Phase 3 · secondary NCT00722371
  • -2.9 vs -1.4 100 mg/45 mg · wk 24 · n 193 · Phase 3 · secondary NCT00722371
  • -3.5 vs -2.2 100 mg q.d. + 30 mg q.d. · wk 24 · n 256 · Phase 3 · secondary NCT00397631
  • -1.3 vs -0.7 30 mg · wk 54 · n 185 · Phase 3 · secondary NCT00722371
  • -1.4 vs -0.1 30 mg · wk 30 · n 133 · Phase 3 · secondary NCT01183013
  • -1.4 vs 0 30 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.2 vs -0.3 30 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.4 30 mg · wk 24 · n 185 · Phase 3 · secondary NCT00722371
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.4 30 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -1.2 vs -0.4 30 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.2 30 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.6 vs -0.7 15 mg · wk 54 · n 176 · Phase 3 · secondary NCT00722371
  • -0.8 vs -0.1 15 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.0 vs 0 15 mg · wk 30 · n 124 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.3 15 mg · wk 24 · n 124 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.4 15 mg · wk 24 · n 176 · Phase 3 · secondary NCT00722371
  • -0.9 vs -0.4 15 mg · wk 18 · n 124 · Phase 3 · secondary NCT01183013
  • -0.6 vs -0.4 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8 vs -0.2 15 mg · wk 6 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.1 vs -0.1 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.1 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -0.1 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs 0 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs 0 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs 0 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.3 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -0.3 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -0.3 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.4 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -0.4 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.4 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.2 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.2 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.2 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
3-point MACE (% with event)—Not posted · NCT01106131—Not posted · NCT00189774

HbA1c, change

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone
-1.0% vs -0.3%−0.8 vs placebo300 mg · wk 26 · n 112NCT01106690
102 other results
  • -0.9% vs -0.3% 100 mg · wk 26 · n 113 · Phase 3 · primary NCT01106690
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.8% vs -0.2% 10 mg · wk 24 · n 149 · Phase 3 · primary NCT01095666
  • -0.8% vs -0.2% 5 mg · wk 24 · n 146 · Phase 3 · primary NCT01095666
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.3% vs -0.4% wk 16 · n 63 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -0.4% vs 0.4% wk 12 · n 66 · Phase 3 · primary NCT00372060
  • -1.2% vs -0.9% 45 mg · wk 54 · n 171 · Phase 3 · primary NCT00722371
  • -0.9% vs -0.4% 45 mg · wk 30 · n 134 · Phase 3 · primary NCT01183013
  • -1.2% vs -1.1% 45 mg · wk 24 · n 171 · Phase 3 · primary NCT00722371
  • -1.4% vs -0.9% 100 mg/15 mg · wk 54 · n 179 · Phase 3 · primary NCT00722371
  • -1.5% vs -0.9% 100 mg/30 mg · wk 54 · n 173 · Phase 3 · primary NCT00722371
  • -1.8% vs -0.9% 100 mg/45 mg · wk 54 · n 188 · Phase 3 · primary NCT00722371
  • -2.4% vs -1.9% 100 mg q.d. + 45 mg q.d. · wk 54 · n 161 · Phase 3 · primary NCT01028391
  • -1.5% vs -1.1% 100 mg/15 mg · wk 24 · n 179 · Phase 3 · primary NCT00722371
  • -1.6% vs -1.1% 100 mg/30 mg · wk 24 · n 173 · Phase 3 · primary NCT00722371
  • -1.8% vs -1.1% 100 mg/45 mg · wk 24 · n 188 · Phase 3 · primary NCT00722371
  • -2.4% vs -1.5% 100 mg q.d. + 30 mg q.d. · wk 24 · n 251 · Phase 3 · primary NCT00397631
  • -1.2% vs -0.9% 30 mg · wk 54 · n 181 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.4% 30 mg · wk 30 · n 134 · Phase 3 · primary NCT01183013
  • -1.2% vs -1.1% 30 mg · wk 24 · n 181 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.7% vs -0.9% 15 mg · wk 54 · n 163 · Phase 3 · primary NCT00722371
  • -0.7% vs -0.4% 15 mg · wk 30 · n 124 · Phase 3 · primary NCT01183013
  • -0.9% vs -1.1% 15 mg · wk 24 · n 163 · Phase 3 · primary NCT00722371
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.4% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.6% vs -0.9% wk 52 · n 50 · Phase 3 · secondary NCT00372060
  • -0.3% vs -0.4% wk 12 · n 63 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.3% vs -0.4% wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1% vs -0.2% wk 4 · n 63 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 45 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 45 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 45 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 45 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 30 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 30 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 30 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.4% 30 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 30 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.8% vs -0.4% 15 mg · wk 30 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 15 mg · wk 24 · n 124 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.4% 15 mg · wk 18 · n 124 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.4% 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT01183013
  • -0.2% vs -0.2% 15 mg · wk 6 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.9% vs -0.4% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.4% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.4% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.4% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.4% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.4% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs 0.2% wk 12 · n 12 · Phase 2 · secondary NCT00443755

Body weight, change (kg)

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone
1.1 vs 1.0+0.1 vs placebo25 mg QD · wk 26 · n 189NCT00286494
21 other results
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -2.6 vs -0.7 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT01095666
  • -1.8 vs -0.7 5 mg · wk 24 · n 147 · Phase 3 · secondary NCT01095666
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.6 wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276

HbA1c below 7%

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone
33% vs 17.5%+15.5 vs placebo10 mg · wk 24 · n 149NCT01095666
4 other results
  • 32.9% vs 17.5% 5 mg · wk 24 · n 146 · Phase 3 · secondary NCT01095666
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 31.7% vs 30% wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119

Fasting plasma glucose, change

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone
-1.8 vs 0.1−2 vs placebo300 mg · wk 26 · n 112NCT01106690
105 other results
  • -1.5 vs 0.1 100 mg · wk 26 · n 113 · Phase 3 · secondary NCT01106690
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -1.5 vs 0.0 10 mg · wk 24 · n 151 · Phase 3 · secondary NCT01095666
  • -1.2 vs 0.0 5 mg · wk 24 · n 146 · Phase 3 · secondary NCT01095666
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.1 vs -0.3 wk 16 · n 63 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.2 vs -0.4 wk 12 · n 63 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.2 wk 12 · n 66 · Phase 3 · secondary NCT00372060
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.0 vs -0.3 wk 8 · n 63 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • 0.3 vs -0.3 wk 4 · n 63 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1.9 vs -0.7 45 mg · wk 54 · n 181 · Phase 3 · secondary NCT00722371
  • -1.6 vs -0.1 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.8 vs 0 45 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.3 45 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -2.1 vs -1.4 45 mg · wk 24 · n 181 · Phase 3 · secondary NCT00722371
  • -1.6 vs -0.4 45 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -1.4 vs -0.4 45 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.2 45 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -1.9 vs -0.7 100 mg/15 mg · wk 54 · n 189 · Phase 3 · secondary NCT00722371
  • -2.1 vs -0.7 100 mg/30 mg · wk 54 · n 181 · Phase 3 · secondary NCT00722371
  • -2.6 vs -0.7 100 mg/45 mg · wk 54 · n 193 · Phase 3 · secondary NCT00722371
  • -3.4 vs -2.9 100 mg q.d. + 45 mg q.d. · wk 54 · n 163 · Phase 3 · secondary NCT01028391
  • -2.3 vs -1.4 100 mg/15 mg · wk 24 · n 189 · Phase 3 · secondary NCT00722371
  • -2.6 vs -1.4 100 mg/30 mg · wk 24 · n 181 · Phase 3 · secondary NCT00722371
  • -2.9 vs -1.4 100 mg/45 mg · wk 24 · n 193 · Phase 3 · secondary NCT00722371
  • -3.5 vs -2.2 100 mg q.d. + 30 mg q.d. · wk 24 · n 256 · Phase 3 · secondary NCT00397631
  • -1.3 vs -0.7 30 mg · wk 54 · n 185 · Phase 3 · secondary NCT00722371
  • -1.4 vs -0.1 30 mg · wk 30 · n 133 · Phase 3 · secondary NCT01183013
  • -1.4 vs 0 30 mg · wk 30 · n 134 · Phase 3 · secondary NCT01183013
  • -1.2 vs -0.3 30 mg · wk 24 · n 134 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.4 30 mg · wk 24 · n 185 · Phase 3 · secondary NCT00722371
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -1.1 vs -0.4 30 mg · wk 18 · n 134 · Phase 3 · secondary NCT01183013
  • -1.2 vs -0.4 30 mg · wk 12 · n 134 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.2 30 mg · wk 6 · n 134 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.6 vs -0.7 15 mg · wk 54 · n 176 · Phase 3 · secondary NCT00722371
  • -0.8 vs -0.1 15 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.0 vs 0 15 mg · wk 30 · n 124 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.3 15 mg · wk 24 · n 124 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.4 15 mg · wk 24 · n 176 · Phase 3 · secondary NCT00722371
  • -0.9 vs -0.4 15 mg · wk 18 · n 124 · Phase 3 · secondary NCT01183013
  • -0.6 vs -0.4 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8 vs -0.2 15 mg · wk 6 · n 124 · Phase 3 · secondary NCT01183013
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.1 vs -0.1 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.1 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -0.1 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs 0 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs 0 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs 0 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -0.3 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -0.3 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -0.3 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.4 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -0.4 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -0.4 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.4 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.2 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.2 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.2 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013

3-point MACE (% with event)

Lobeglitazone
—Not posted · NCT01106131
Pioglitazone
—Not posted · NCT00189774
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Lobeglitazone
Drug-drug interaction study in healthy subjects: for warfarin AUC, the geometric mean ratios for warfarin plus lobeglitazone compared to warfarin alone were 1.0076 for R-warfarin and 0.9880 for S-warfarin, and maximum observed plasma concentration values were 1.0167 and 1.0028, all contained in the interval 0.80 to 1.25. Lobeglitazone had no effect on the area under the effect-time curve of INR or factor VII activity (geometric mean ratios 1.0091 and 0.9355) and no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin; concomitant administration was well tolerated. NCT02002611 · Phase 1 · design grade: weak · reviewed ClinicalTrials.gov result
HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. NCT03739125 · Phase 3 · design grade: moderate · publication or press release
HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior. NCT01106131 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lobeglitazone: 0 of 4 rows · Pioglitazone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPioglitazone
Dropout rate
34.4%a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 41 more results
50%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
—30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
47.4%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
4.6%10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
29.7%45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
27.9%30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
34.4%15 mg / 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
28.6%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
33.8%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
27.8%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.4%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
8%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
7.9%Pioglitazone
NCT01289119 · Phase 3 · registry result, not featured evidence
6.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
27.4%45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
20.9%100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
22.9%100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
22.2%100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
27.9%30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
31.3%15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
5.8%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
20.6%15 mg and Metformin 850 mg BID
NCT00770653 · Phase 3 · registry result, not featured evidence · combination
8.5%100 mg q.d. + 45 mg q.d.
NCT01028391 · Phase 3 · registry result, not featured evidence · combination
11.5%100 mg q.d. + 30 mg q.d.
NCT00397631 · Phase 3 · registry result, not featured evidence · combination
4.5%Sitagliptin / Sitagliptin
NCT00372060 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Sitagliptin (Data Thro
NCT00372060 · Phase 3 · registry result, not featured evidence
19.6%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
22.3%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
14.9%100 mg
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
14.3%
NCT00443755 · Phase 2 · registry result, not featured evidence
9.6%100 mg + 30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence · combination
3.7%30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 41 more results
0%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
—30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
5.3%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
2%10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
0.7%5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
3.6%45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
5.7%30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
4.6%15 mg / 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.9%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
4.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0.9%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
1.6%Pioglitazone
NCT01289119 · Phase 3 · registry result, not featured evidence
0%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
4.3%45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
2.6%100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
3.5%100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
1.7%100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
3.9%30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
5.7%15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
8.4%15 mg and Metformin 850 mg BID
NCT00770653 · Phase 3 · registry result, not featured evidence · combination
2.4%100 mg q.d. + 45 mg q.d.
NCT01028391 · Phase 3 · registry result, not featured evidence · combination
1.9%100 mg q.d. + 30 mg q.d.
NCT00397631 · Phase 3 · registry result, not featured evidence · combination
3%Sitagliptin / Sitagliptin
NCT00372060 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Sitagliptin (Data Thro
NCT00372060 · Phase 3 · registry result, not featured evidence
3%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
4.1%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
6.3%100 mg
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT00443755 · Phase 2 · registry result, not featured evidence
1.9%100 mg + 30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence · combination
0%30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence
Serious AEs
0%a
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 41 more results
0%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
3.9%30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
5.9%15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
2%10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
3.6%45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
6.4%30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
6.9%15 mg / 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.1%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.3%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
—300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
3.5%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
2.7%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
7.1%100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
0%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0%Pioglitazone
NCT01289119 · Phase 3 · registry result, not featured evidence
1.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
4.8%45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
5.2%100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
6.5%100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
3%100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
2.1%30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
4.3%15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
11.1%15 mg and Metformin 850 mg BID
NCT00770653 · Phase 3 · registry result, not featured evidence · combination
3%100 mg q.d. + 45 mg q.d.
NCT01028391 · Phase 3 · registry result, not featured evidence · combination
—100 mg q.d. + 30 mg q.d.
NCT00397631 · Phase 3 · registry result, not featured evidence · combination
—Sitagliptin / Sitagliptin
NCT00372060 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Sitagliptin (Data Thro
NCT00372060 · Phase 3 · registry result, not featured evidence
6.5%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.5%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.9%100 mg
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%
NCT00443755 · Phase 2 · registry result, not featured evidence
1.9%100 mg + 30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence · combination
0%30 mg
NCT00511108 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
nausea 25.2%
hypoglycemia 13.6%
peripheral edema 4.9%
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
show 37 more results
30 mg
oedema 11.8%
eyelid oedema 5.9%
folliculitis 5.9%
NCT01972724 · Phase 4 · registry result, not featured evidence
30 mg
conjunctival haemorrhage 0%
eyelid oedema 0%
folliculitis 0%
NCT01972724 · Phase 4 · registry result, not featured evidence
15 mg
conjunctival haemorrhage 5.9%
ligament injury 5.9%
nasopharyngitis 5.9%
NCT01972724 · Phase 4 · registry result, not featured evidence
10 mg
hyperlipidaemia 11.8% (placebo 11%)
urinary tract infection 6.6% (placebo 4.8%)
nasopharyngitis 4.6% (placebo 3.4%)
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
5 mg
hyperlipidaemia 12.2% (placebo 11%)
upper respiratory tract infection 9.5% (placebo 2.1%)
nasopharyngitis 6.1% (placebo 3.4%)
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
45 mg
oedema peripheral 8%
back pain 7.2%
arthralgia 6.5%
NCT01183013 · Phase 3 · registry result, not featured evidence
30 mg
oedema peripheral 7.9%
hyperglycaemia 7.1%
nasopharyngitis 7.1%
NCT01183013 · Phase 3 · registry result, not featured evidence
15 mg / 30 mg
oedema peripheral 9.9%
back pain 9.2%
hypertension 9.2%
NCT01183013 · Phase 3 · registry result, not featured evidence
5 mg + 15 mg / 5 mg + 30 mg
diarrhoea 7.9%
nasopharyngitis 7.1%
back pain 6.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 30 mg
oedema 9%
dizziness 6.8%
oedema peripheral 6.8%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 45 mg
oedema peripheral 11.3%
back pain 9%
urinary tract infection 5.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
300 mg
nasopharyngitis 9.6% (placebo 5.2%)
pollakiuria 6.1% (placebo 0.9%)
arthralgia 5.3% (placebo 1.7%)
NCT01106690 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.2% (placebo 5.2%)
arthralgia 7.9% (placebo 1.7%)
urinary tract infection 7.9% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 8% (placebo 6.1%)
back pain 7.1% (placebo 2.6%)
nasopharyngitis 5.3% (placebo 5.2%)
NCT01106690 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 12.4% (placebo 6.1%)
nasopharyngitis 9.7% (placebo 5.2%)
back pain 8.8% (placebo 2.6%)
NCT01106690 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 3% (placebo 3.3%)
blood triglycerides increased 2% (placebo 1.1%)
urinary tract infection 2% (placebo 6.5%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 9.5% (placebo 3.3%)
blood triglycerides increased 6.3% (placebo 1.1%)
hyperlipidaemia 6.3% (placebo 1.1%)
NCT01289119 · Phase 3 · registry result, not featured evidence
hyperlipidaemia 21.3% (placebo 1.1%)
urinary tract infection 6.6% (placebo 6.5%)
upper respiratory tract infection 3.3% (placebo 3.3%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
45 mg
hypoglycaemia 8.7%
upper respiratory tract infection 5.2%
headache 4.8%
NCT00722371 · Phase 3 · registry result, not featured evidence
100 mg/15 mg
hypoglycaemia 8.7%
hypertension 5.7%
nasopharyngitis 5.2%
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
100 mg/30 mg
hypoglycaemia 11.3%
nasopharyngitis 6.5%
headache 6.1%
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
100 mg/45 mg
hypoglycaemia 10.4%
upper respiratory tract infection 4.8%
nasopharyngitis 3.5%
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
30 mg
hypoglycaemia 9.4%
nasopharyngitis 5.2%
headache 3.9%
NCT00722371 · Phase 3 · registry result, not featured evidence
15 mg
hypoglycaemia 8.7%
nasopharyngitis 4.3%
headache 2.6%
NCT00722371 · Phase 3 · registry result, not featured evidence
Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
upper respiratory tract infection 7.2%
nasopharyngitis 6.9%
hypertension 5.9%
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 9.3% (placebo 8.5%)
upper respiratory tract infection 3.5% (placebo 7.7%)
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
15 mg and Metformin 850 mg BID
nasopharyngitis 15.7%
diarrhoea 9.2%
arthralgia 5.2%
NCT00770653 · Phase 3 · registry result, not featured evidence · combination
100 mg q.d. + 45 mg q.d.
all infections and infestations 4.9%
nasopharyngitis 4.9%
NCT01028391 · Phase 3 · registry result, not featured evidence · combination
100 mg q.d. + 30 mg q.d.
any nervous system disorders 3.4%
headache 3.4%
any infections and infestations 3.1%
NCT00397631 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 16.7% (placebo 25%)
upper respiratory tract inflammation 13.6% (placebo 4.4%)
weight increased 3% (placebo 0%)
NCT00372060 · Phase 3 · registry result, not featured evidence
25 mg QD
nasopharyngitis 7% (placebo 6.2%)
influenza 5.5% (placebo 4.1%)
oedema peripheral 5.5% (placebo 7.2%)
NCT00286494 · Phase 3 · registry result, not featured evidence
12.5 mg QD
oedema peripheral 6.1% (placebo 7.2%)
upper respiratory tract infection 5.6% (placebo 5.2%)
nausea 4.5% (placebo 2.1%)
NCT00286494 · Phase 3 · registry result, not featured evidence
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 11.5%
blood creatine phosphokinase increased 3.5%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 4.5%
blood creatine phosphokinase increased 0%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
100 mg + 30 mg
blood glucose increased 0% (placebo 5.7%)
headache 0% (placebo 5.7%)
hyperglycaemia 0% (placebo 0%)
NCT00511108 · Phase 1 · registry result, not featured evidence · combination
30 mg
upper respiratory tract infection 5.6% (placebo 5.7%)
blood glucose increased 0% (placebo 5.7%)
headache 0% (placebo 5.7%)
NCT00511108 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 41 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pioglitazone

HbA1c 6.9% (n=103) vs 6.4% (n=114) Conventional Therapy @ 156wk
absolute value · percentage points
NCT01107717 · Phase 4 · registry result, not featured evidence · combination
Treatment Failure 32% (n=103) vs 51.8% (n=114) Conventional Therapy @ 156wk
event count · % of participants
NCT01107717 · Phase 4 · registry result, not featured evidence · combination · converted to % from 33 number of participants as posted
HbA1c -0.003% (n=17) @ 24wk30 mg
absolute change · percentage points
No placebo or comparator arm
NCT01972724 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.0275% (n=76) @ 24wk30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
-0.0003% (n=17) @ 24wk15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -0.4278 mmol/L @ 24wk30 mg
absolute change · mmol/L
No placebo or comparator arm
NCT01972724 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.4412 mmol/L @ 24wk30 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
0.6727 mmol/L @ 24wk15 mg
NCT01972724 · Phase 4 · registry result, not featured evidence
HbA1c -0.87% (n=134) vs -0.39% (n=130) linagliptin @ 30wk45 mg
absolute change · percentage points
NCT01183013 · Phase 3 · registry result, not featured evidence
show 102 more results
-0.2% (n=134) vs -0.23% (n=130) linagliptin @ 6wk45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.59% (n=134) vs -0.36% (n=130) linagliptin @ 12wk45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.82% (n=134) vs -0.39% (n=130) linagliptin @ 18wk45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.87% (n=134) vs -0.39% (n=130) linagliptin @ 24wk45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.94% (n=134) vs -0.37% (n=130) linagliptin @ 30wk45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-1.2% (n=171) vs -1.09% (n=172) Sitagliptin @ 24wk45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-1.23% (n=171) vs -0.93% (n=172) Sitagliptin @ 54wk45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-1.03% (n=112) vs -0.26% (n=114) placebo @ 26wk300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-0.89% (n=113) vs -0.26% (n=114) placebo @ 26wk100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence
-0.85% (n=163) vs -0.15% (n=174) placebo @ 24wk100 mg
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
-0.8% (n=195) vs -0.19% (n=95) placebo @ 26wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.45% (n=176) vs -0.14% (n=90) placebo @ 4wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.73% (n=195) vs -0.18% (n=95) placebo @ 8wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.82% (n=195) vs -0.23% (n=95) placebo @ 12wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.84% (n=195) vs -0.26% (n=95) placebo @ 16wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.82% (n=195) vs -0.27% (n=95) placebo @ 20wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.66% (n=196) vs -0.19% (n=95) placebo @ 26wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.4% (n=182) vs -0.14% (n=90) placebo @ 4wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.6% (n=196) vs -0.18% (n=95) placebo @ 8wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.7% (n=196) vs -0.23% (n=95) placebo @ 12wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.7% (n=196) vs -0.26% (n=95) placebo @ 16wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-0.68% (n=196) vs -0.27% (n=95) placebo @ 20wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
-1.53% (n=179) vs -1.09% (n=172) Sitagliptin @ 24wk100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-1.63% (n=173) vs -1.09% (n=172) Sitagliptin @ 24wk100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-1.81% (n=188) vs -1.09% (n=172) Sitagliptin @ 24wk100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-1.45% (n=179) vs -0.93% (n=172) Sitagliptin @ 54wk100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-1.49% (n=173) vs -0.93% (n=172) Sitagliptin @ 54wk100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-1.78% (n=188) vs -0.93% (n=172) Sitagliptin @ 54wk100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-2.37% (n=161) vs -1.86% (n=149) Pioglitazone 45 mg q.d. @ 54wk100 mg q.d. + 45 mg q.d.
NCT01028391 · Phase 3 · registry result, not featured evidence · combination
-2.38% (n=251) vs -1.49% (n=246) Pioglitazone @ 24wk100 mg q.d. + 30 mg q.d.
NCT00397631 · Phase 3 · registry result, not featured evidence · combination
-0.69% (n=134) vs -0.39% (n=130) linagliptin @ 30wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.16% (n=134) vs -0.23% (n=130) linagliptin @ 6wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.43% (n=134) vs -0.36% (n=130) linagliptin @ 12wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.58% (n=134) vs -0.39% (n=130) linagliptin @ 18wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.67% (n=134) vs -0.39% (n=130) linagliptin @ 24wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.73% (n=134) vs -0.37% (n=130) linagliptin @ 30wk30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-1.21% (n=181) vs -1.09% (n=172) Sitagliptin @ 24wk30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-1.16% (n=181) vs -0.93% (n=172) Sitagliptin @ 54wk30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-0.89% (n=303) vs -0.42% (n=306) Pioglitazone 45 mg + Metformin @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.7% (n=303) vs -0.29% (n=306) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.42% (n=303) vs -0.15% (n=306) Pioglitazone 45 mg + Metformin @ 4wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.71% (n=303) vs -0.27% (n=306) Pioglitazone 45 mg + Metformin @ 8wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.85% (n=303) vs -0.35% (n=306) Pioglitazone 45 mg + Metformin @ 12wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.91% (n=303) vs -0.43% (n=306) Pioglitazone 45 mg + Metformin @ 16wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.91% (n=303) vs -0.45% (n=306) Pioglitazone 45 mg + Metformin @ 20wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.82% (n=303) vs -0.37% (n=306) Pioglitazone 45 mg + Metformin @ 34wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.8% (n=303) vs -0.36% (n=306) Pioglitazone 45 mg + Metformin @ 42wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-0.22% (n=111) vs -0.04% (n=115) Pioglitazone @ 2wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.46% (n=113) vs -0.1% (n=115) Pioglitazone @ 4wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=113) vs -0.17% (n=115) Pioglitazone @ 8wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.97% (n=113) vs -0.19% (n=115) Pioglitazone @ 12wkalogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.66% (n=124) vs -0.39% (n=130) linagliptin @ 30wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.22% (n=124) vs -0.23% (n=130) linagliptin @ 6wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.47% (n=124) vs -0.36% (n=130) linagliptin @ 12wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.63% (n=124) vs -0.39% (n=130) linagliptin @ 18wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.75% (n=124) vs -0.39% (n=130) linagliptin @ 24wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.77% (n=124) vs -0.37% (n=130) linagliptin @ 30wk15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
-0.88% (n=163) vs -1.09% (n=172) Sitagliptin @ 24wk15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-0.74% (n=163) vs -0.93% (n=172) Sitagliptin @ 54wk15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-0.22% (n=110) vs -0.04% (n=115) Pioglitazone @ 2wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.47% (n=111) vs -0.1% (n=115) Pioglitazone @ 4wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.76% (n=111) vs -0.17% (n=115) Pioglitazone @ 8wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.91% (n=111) vs -0.19% (n=115) Pioglitazone @ 12wkalogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
-0.85% (n=149) vs -0.23% (n=139) placebo @ 24wk10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
-0.82% (n=146) vs -0.23% (n=139) placebo @ 24wk5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
-0.83% (n=120) vs -0.39% (n=130) linagliptin @ 30wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.06% (n=125) vs -0.39% (n=130) linagliptin @ 30wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.28% (n=126) vs -0.39% (n=130) linagliptin @ 30wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.43% (n=120) vs -0.23% (n=130) linagliptin @ 6wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.47% (n=125) vs -0.23% (n=130) linagliptin @ 6wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.62% (n=126) vs -0.23% (n=130) linagliptin @ 6wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.71% (n=120) vs -0.36% (n=130) linagliptin @ 12wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.92% (n=125) vs -0.36% (n=130) linagliptin @ 12wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.01% (n=126) vs -0.36% (n=130) linagliptin @ 12wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.81% (n=120) vs -0.39% (n=130) linagliptin @ 18wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.07% (n=125) vs -0.39% (n=130) linagliptin @ 18wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.22% (n=126) vs -0.39% (n=130) linagliptin @ 18wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.84% (n=120) vs -0.39% (n=130) linagliptin @ 24wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.1% (n=125) vs -0.39% (n=130) linagliptin @ 24wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.23% (n=126) vs -0.39% (n=130) linagliptin @ 24wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.87% (n=120) vs -0.37% (n=130) linagliptin @ 30wk5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.09% (n=125) vs -0.37% (n=130) linagliptin @ 30wk5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-1.27% (n=126) vs -0.37% (n=130) linagliptin @ 30wk5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
-0.91% (n=98) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.25% (n=63) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.76% (n=60) vs -0.42% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.43% (n=99) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.09% (n=63) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.44% (n=61) vs -0.24% (n=92) placebo @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.66% (n=99) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.31% (n=63) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.7% (n=61) vs -0.39% (n=92) placebo @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=99) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.25% (n=63) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.77% (n=61) vs -0.41% (n=92) placebo @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.06% (n=252) vs -0.56% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.41% (n=252) vs -0.03% (n=128) placebo @ 6wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.85% (n=252) vs -0.35% (n=128) placebo @ 12wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-1.06% (n=252) vs -0.55% (n=128) placebo @ 18wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
-0.4% (n=66) vs 0.4% (n=68) placebo @ 12wk
NCT00372060 · Phase 3 · registry result, not featured evidence
-0.6% (n=50) vs -0.9% (n=59) placebo @ 52wk
NCT00372060 · Phase 3 · registry result, not featured evidence
-0.35% (n=12) vs 0.19% (n=13) placebo @ 12wk
NCT00443755 · Phase 2 · registry result, not featured evidence
Fasting Plasma Glucose -1.59 vs -0.08 linagliptin mmol/L @ 30wk45 mg
absolute change · mmol/L
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -28.69 mg/dL as posted
show 105 more results
-0.87 vs -0.24 linagliptin mmol/L @ 6wk*45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15.72 mg/dL as posted
-1.4 vs -0.41 linagliptin mmol/L @ 12wk*45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -25.3 mg/dL as posted
-1.59 vs -0.39 linagliptin mmol/L @ 18wk*45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -28.68 mg/dL as posted
-1.54 vs -0.26 linagliptin mmol/L @ 24wk*45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -27.67 mg/dL as posted
-1.76 vs 0 linagliptin mmol/L @ 30wk*45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -31.76 mg/dL as posted
-2.08 vs -1.35 Sitagliptin mmol/L @ 24wk*45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -37.4 mg/dL as posted
-1.85 vs -0.73 Sitagliptin mmol/L @ 54wk*45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.3 mg/dL as posted
-1.84 vs 0.14 placebo mmol/L @ 26wk*300 mg
NCT01106690 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.2 mg/dL as posted
-1.49 vs 0.14 placebo mmol/L @ 26wk*100 mg
NCT01106690 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.8 mg/dL as posted
-0.93 vs 0.06 placebo mmol/L @ 24wk*100 mg
NCT00086502 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.7 mg/dL as posted
-1.01 vs -0.15 placebo mmol/L @ 1wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.2 mg/dL as posted
-1.18 vs -0.1 placebo mmol/L @ 2wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.2 mg/dL as posted
-1.44 vs -0.17 placebo mmol/L @ 4wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26 mg/dL as posted
-1.5 vs -0.34 placebo mmol/L @ 8wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -27.1 mg/dL as posted
-1.45 vs -0.55 placebo mmol/L @ 12wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.2 mg/dL as posted
-1.27 vs -0.46 placebo mmol/L @ 16wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.8 mg/dL as posted
-1.2 vs -0.36 placebo mmol/L @ 20wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.6 mg/dL as posted
-1.1 vs -0.32 placebo mmol/L @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.9 mg/dL as posted
-0.79 vs -0.15 placebo mmol/L @ 1wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.2 mg/dL as posted
-1.17 vs -0.1 placebo mmol/L @ 2wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21 mg/dL as posted
-1.32 vs -0.17 placebo mmol/L @ 4wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -23.7 mg/dL as posted
-1.25 vs -0.34 placebo mmol/L @ 8wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -22.6 mg/dL as posted
-1.13 vs -0.55 placebo mmol/L @ 12wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.4 mg/dL as posted
-1.02 vs -0.46 placebo mmol/L @ 16wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -18.3 mg/dL as posted
-1.22 vs -0.36 placebo mmol/L @ 20wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.9 mg/dL as posted
-1.09 vs -0.32 placebo mmol/L @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.7 mg/dL as posted
-2.28 vs -1.35 Sitagliptin mmol/L @ 24wk*100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -41 mg/dL as posted
-2.6 vs -1.35 Sitagliptin mmol/L @ 24wk*100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -46.9 mg/dL as posted
-2.89 vs -1.35 Sitagliptin mmol/L @ 24wk*100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -52 mg/dL as posted
-1.88 vs -0.73 Sitagliptin mmol/L @ 54wk*100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.9 mg/dL as posted
-2.06 vs -0.73 Sitagliptin mmol/L @ 54wk*100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted
-2.65 vs -0.73 Sitagliptin mmol/L @ 54wk*100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -47.8 mg/dL as posted
-3.4 vs -2.93 Pioglitazone 45 mg q.d. mmol/L @ 54wk*100 mg q.d. + 45 mg q.d.
NCT01028391 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -61.3 mg/dL as posted
-3.5 vs -2.23 Pioglitazone mmol/L @ 24wk*100 mg q.d. + 30 mg q.d.
NCT00397631 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -63 mg/dL as posted
-1.41 vs -0.08 linagliptin mmol/L @ 30wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -25.49 mg/dL as posted
-0.91 vs -0.24 linagliptin mmol/L @ 6wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.38 mg/dL as posted
-1.19 vs -0.41 linagliptin mmol/L @ 12wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.36 mg/dL as posted
-1.15 vs -0.39 linagliptin mmol/L @ 18wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.69 mg/dL as posted
-1.2 vs -0.26 linagliptin mmol/L @ 24wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.57 mg/dL as posted
-1.45 vs 0 linagliptin mmol/L @ 30wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -26.09 mg/dL as posted
-1.66 vs -1.35 Sitagliptin mmol/L @ 24wk*30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -29.9 mg/dL as posted
-1.33 vs -0.73 Sitagliptin mmol/L @ 54wk*30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -24 mg/dL as posted
-0.86 vs -0.03 Pioglitazone 45 mg + Metformin mmol/L @ 2wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -15.5 mg/dL as posted
-0.98 vs -0.08 Pioglitazone 45 mg + Metformin mmol/L @ 4wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.7 mg/dL as posted
-1.06 vs -0.32 Pioglitazone 45 mg + Metformin mmol/L @ 8wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.1 mg/dL as posted
-1.09 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 12wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.6 mg/dL as posted
-1 vs -0.25 Pioglitazone 45 mg + Metformin mmol/L @ 16wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -18 mg/dL as posted
-0.91 vs -0.32 Pioglitazone 45 mg + Metformin mmol/L @ 20wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -16.4 mg/dL as posted
-0.95 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 26wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.75 vs -0.34 Pioglitazone 45 mg + Metformin mmol/L @ 34wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.6 mg/dL as posted
-0.88 vs -0.27 Pioglitazone 45 mg + Metformin mmol/L @ 42wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -15.9 mg/dL as posted
-0.81 vs -0.21 Pioglitazone 45 mg + Metformin mmol/L @ 52wk*Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -14.6 mg/dL as posted
-0.94 vs -0.22 Pioglitazone mmol/L @ 2wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17 mg/dL as posted
-0.99 vs -0.17 Pioglitazone mmol/L @ 4wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.9 mg/dL as posted
-1.18 vs -0.23 Pioglitazone mmol/L @ 8wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.3 mg/dL as posted
-1.05 vs -0.13 Pioglitazone mmol/L @ 12wk*alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.9 mg/dL as posted
-0.84 vs -0.08 linagliptin mmol/L @ 30wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -15.16 mg/dL as posted
-0.8 vs -0.24 linagliptin mmol/L @ 6wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -14.43 mg/dL as posted
-0.59 vs -0.41 linagliptin mmol/L @ 12wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.63 mg/dL as posted
-0.93 vs -0.39 linagliptin mmol/L @ 18wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.68 mg/dL as posted
-0.9 vs -0.26 linagliptin mmol/L @ 24wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.25 mg/dL as posted
-0.98 vs 0 linagliptin mmol/L @ 30wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -17.66 mg/dL as posted
-1.08 vs -1.35 Sitagliptin mmol/L @ 24wk*15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.5 mg/dL as posted
-0.58 vs -0.73 Sitagliptin mmol/L @ 54wk*15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.5 mg/dL as posted
-0.71 vs -0.22 Pioglitazone mmol/L @ 2wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -12.8 mg/dL as posted
-0.8 vs -0.17 Pioglitazone mmol/L @ 4wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.4 mg/dL as posted
-0.95 vs -0.23 Pioglitazone mmol/L @ 8wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.83 vs -0.13 Pioglitazone mmol/L @ 12wk*alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.9 mg/dL as posted
-1.48 vs 0.03 placebo mmol/L @ 24wk*10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -26.6 mg/dL as posted
-1.2 vs 0.03 placebo mmol/L @ 24wk*5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -21.6 mg/dL as posted
-1.05 vs -0.08 linagliptin mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -18.84 mg/dL as posted
-1.52 vs -0.08 linagliptin mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.33 mg/dL as posted
-1.95 vs -0.08 linagliptin mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.19 mg/dL as posted
-1.07 vs -0.24 linagliptin mmol/L @ 6wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.25 mg/dL as posted
-1.49 vs -0.24 linagliptin mmol/L @ 6wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -26.89 mg/dL as posted
-1.57 vs -0.24 linagliptin mmol/L @ 6wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -28.36 mg/dL as posted
-1 vs -0.41 linagliptin mmol/L @ 12wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.99 mg/dL as posted
-1.73 vs -0.41 linagliptin mmol/L @ 12wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.25 mg/dL as posted
-1.58 vs -0.41 linagliptin mmol/L @ 12wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -28.53 mg/dL as posted
-1.06 vs -0.39 linagliptin mmol/L @ 18wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.01 mg/dL as posted
-1.73 vs -0.39 linagliptin mmol/L @ 18wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.22 mg/dL as posted
-1.7 vs -0.39 linagliptin mmol/L @ 18wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.66 mg/dL as posted
-0.93 vs -0.26 linagliptin mmol/L @ 24wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -16.68 mg/dL as posted
-1.75 vs -0.26 linagliptin mmol/L @ 24wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.48 mg/dL as posted
-1.75 vs -0.26 linagliptin mmol/L @ 24wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -31.49 mg/dL as posted
-1 vs 0 linagliptin mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -17.93 mg/dL as posted
-1.5 vs 0 linagliptin mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.11 mg/dL as posted
-1.89 vs 0 linagliptin mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -34.04 mg/dL as posted
-0.985 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0.284 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.985 vs -0.331 placebo mmol/L @ 4wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.265 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.038 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.924 vs -0.33 placebo mmol/L @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.27 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.187 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-1.177 vs -0.411 placebo mmol/L @ 12wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.24 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.114 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-1.07 vs -0.317 placebo mmol/L @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-1.81 vs -1.02 placebo mmol/L @ 24wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -32.6 mg/dL as posted
-1.85 vs -0.94 placebo mmol/L @ 6wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.3 mg/dL as posted
-1.88 vs -1.14 placebo mmol/L @ 12wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.8 mg/dL as posted
-1.84 vs -1.07 placebo mmol/L @ 18wk*
NCT00641043 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -33.2 mg/dL as posted
-0.68 vs 0.24 placebo mmol/L @ 12wk*
NCT00372060 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -12.2 mg/dL as posted
PMG 2-hr Change mg/dL -66.6 vs -51.1 Sitagliptin mg/dL @ 24wk45 mg
absolute change · mg/dL
NCT00722371 · Phase 3 · registry result, not featured evidence
show 13 more results
-58.2 vs -37 Sitagliptin mg/dL @ 54wk45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-69.2 vs -51.1 Sitagliptin mg/dL @ 24wk100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-85.5 vs -51.1 Sitagliptin mg/dL @ 24wk100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-93.8 vs -51.1 Sitagliptin mg/dL @ 24wk100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-64.7 vs -37 Sitagliptin mg/dL @ 54wk100 mg/15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-69.7 vs -37 Sitagliptin mg/dL @ 54wk100 mg/30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-88.2 vs -37 Sitagliptin mg/dL @ 54wk100 mg/45 mg
NCT00722371 · Phase 3 · registry result, not featured evidence · combination
-52.5 vs -51.1 Sitagliptin mg/dL @ 24wk30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-46.8 vs -37 Sitagliptin mg/dL @ 54wk30 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-30.6 vs -51.1 Sitagliptin mg/dL @ 24wk15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-26.7 vs -37 Sitagliptin mg/dL @ 54wk15 mg
NCT00722371 · Phase 3 · registry result, not featured evidence
-64.6 vs -15.5 placebo mg/dL @ 24wk10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
-57.8 vs -15.5 placebo mg/dL @ 24wk5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
Weight 0.39 vs 0.36 placebo kg @ 8wk25 mg QD
absolute change · kg
NCT00286494 · Phase 3 · registry result, not featured evidence
show 21 more results
0.64 vs 0.6 placebo kg @ 12wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.93 vs 0.94 placebo kg @ 20wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.09 vs 1.04 placebo kg @ 26wk25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.46 vs 0.36 placebo kg @ 8wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.74 vs 0.6 placebo kg @ 12wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.14 vs 0.94 placebo kg @ 20wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
1.46 vs 1.04 placebo kg @ 26wk12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
0.18 vs 0.32 Pioglitazone 45 mg + Metformin kg @ 4wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.31 vs 0.51 Pioglitazone 45 mg + Metformin kg @ 8wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.35 vs 0.64 Pioglitazone 45 mg + Metformin kg @ 12wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
0.73 vs 0.97 Pioglitazone 45 mg + Metformin kg @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.09 vs 1.52 Pioglitazone 45 mg + Metformin kg @ 42wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.1 vs 1.6 Pioglitazone 45 mg + Metformin kg @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
-2.56 vs -0.74 placebo kg @ 24wk10 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
-1.84 vs -0.74 placebo kg @ 24wk5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
-0.43 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.74 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.15 vs -1.04 placebo kg @ 8wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.76 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
-0.68 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence
-0.1 vs -1.55 placebo kg @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7% 33% (n=149) vs 17.5% (n=139) placebo @ 24wk10 mg
responder rate · % of participants
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
32.9% (n=146) vs 17.5% (n=139) placebo @ 24wk5 mg
NCT01095666 · Phase 3 · registry result, not featured evidence · combination
55.1% (n=98) vs 30% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
31.7% (n=63) vs 30% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence
61.7% (n=60) vs 30% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7% 52.7% (n=129) vs 23.4% (n=124) linagliptin @ 30wk45 mg
event count · % of participants
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 68 participants as posted
show 5 more results
44% (n=125) vs 23.4% (n=124) linagliptin @ 30wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 55 participants as posted
32.2% (n=121) vs 23.4% (n=124) linagliptin @ 30wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 39 participants as posted
40.2% (n=112) vs 23.4% (n=124) linagliptin @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 45 participants as posted
51.7% (n=118) vs 23.4% (n=124) linagliptin @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 61 participants as posted
66.9% (n=121) vs 23.4% (n=124) linagliptin @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 81 participants as posted
HbA1c Less Than 6.5% 29.1% (n=134) vs 10.9% (n=129) linagliptin @ 30wk45 mg
event count · % of participants
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 39 participants as posted
show 5 more results
21.2% (n=132) vs 10.9% (n=129) linagliptin @ 30wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 28 participants as posted
16.1% (n=124) vs 10.9% (n=129) linagliptin @ 30wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 20 participants as posted
20% (n=120) vs 10.9% (n=129) linagliptin @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 24 participants as posted
30.9% (n=123) vs 10.9% (n=129) linagliptin @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 38 participants as posted
34.4% (n=125) vs 10.9% (n=129) linagliptin @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 43 participants as posted
HbA1c Decrease 0.5 67.2% (n=134) vs 41.5% (n=130) linagliptin @ 30wk45 mg
event count · % of participants
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 90 participants as posted
show 7 more results
64.3% (n=199) vs 26.8% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 128 participants as posted
59.9% (n=197) vs 26.8% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 118 participants as posted
61.9% (n=134) vs 41.5% (n=130) linagliptin @ 30wk*30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 83 participants as posted
63.7% (n=124) vs 41.5% (n=130) linagliptin @ 30wk*15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to % from 79 participants as posted
65.8% (n=120) vs 41.5% (n=130) linagliptin @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 79 participants as posted
72.8% (n=125) vs 41.5% (n=130) linagliptin @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 91 participants as posted
84.9% (n=126) vs 41.5% (n=130) linagliptin @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to % from 107 participants as posted

+ 44 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lobeglitazone's landscape · Pioglitazone's landscape